CMO Cytovance adds 1,000L bioreactor for trial supplies

CMO Cytovance adds 1,000L bioreactor for trial supplies

Related tags Biotechnology Investment

Cytovance Biologics has added a 1,000L bioreactor at its Oklahoma site to support scale-up as clients move through clinical trials.

After receiving investment last year US-based CMO (contract manufacturing organisation) Cytovance strengthened its biologics capabilities by acquiring a site and assets from Genzyme. Installation of a 1,000L bioreactor has now further boosted the CMO’s operations in Oklahoma, US.

The decision to expand our capabilities was made with careful consideration of our clients' needs. The additional state of the art bioreactor will allow Cytovance to provide clinical material to key clients as they move through the clinic​”, Darren Head, president & CEO of Cytovance, said.

Cytovance now has 100L, 500L and 1,000L bioreactors, as well as a 100L wave system and a 100L microbial manufacturing train. Using these tools Cytovance can supply clients with antibodies and recombinant proteins and support development of analytical methods and production processes.

News of the bioreactor comes days after Cytovance bolstered its business development team. Valerie McDonnell, formerly of Althea Technologies, has joined Cytovance as vice president of sales and business development.

Equity investment

In March Great Point Partners invested $22.5m (€17.1m) in Cytovance. The funds allowed Cytovance to move into former Genzyme laboratories and buy bioprocess and analytical equipment from the biotech.

Speaking at the time of the investment Head said Great Point Partners “recognised the potential growth opportunities for Cytovance with additional working capital​”. Addition of a bigger bioreactor continues the growth strategy.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers